초록 ▼

Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m2 for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combinatio

Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m2 for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.

대표청구항 ▼

The invention claimed is: 1. A method of treating a human body having cancer comprising administering an effective therapeutic amount of ET-743 in combination with an effective therapeutic amount of a 5-fluorouracil pro-drug. 2. The method according to claim 1, wherein ET-743 is administered in c

The invention claimed is: 1. A method of treating a human body having cancer comprising administering an effective therapeutic amount of ET-743 in combination with an effective therapeutic amount of a 5-fluorouracil pro-drug. 2. The method according to claim 1, wherein ET-743 is administered in combination with capecitabine. 3. The method according to claim 2, wherein capecitabine and ET-743 are provided as separate medicaments for administration at different times. 4. The method according to claim 3, wherein capecitabine is administered in a dose range between 1500 to 2500 mg/m2/day. 5. The method according to claim 3, wherein ET-743 is administered in a dose range between 0.75 and 1.4 mg/m2. 6. The method according to claim 4 or 5, wherein capecitabine is administered in a dosage of up to 2000 mg/m2/day and ET-743 is administered in a dosage of up to 1.2 mg/m2. 7. The method according to claim 6, wherein capecitabine is administered in a dosage about 1600 mg/m2/day and ET-743 is administered in a dosage about 0.9 mg/m2. 8. The method according to claim 4 or 5, wherein capecitabine is orally administered. 9. The method according to claim 8, wherein ET-743 is administered by intravenous injection. 10. The method according to claim 9, wherein the infusion time for intravenous injection of ET-743 is up to 24 hours. 11. The method according to claim 10, wherein the infusion time for intravenous injection of ET-743 is about 3 hours for ET-743. 12. The method according to claim 9, where the infusions of ET-743 are carried out at an interval of 1 to 6 weeks. 13. The method according to claim 12, wherein the infusion of ET-743 is carried out once every 21 days. 14. The method according to claim 13, wherein the infusion of ET-743 is carried out on day 1 and the administration of capecitabine from days 2 to 15, every 21 days. 15. The method according to claim 14, wherein capecitabine is administered twice-daily. 16. A method according to claim 1, in which the patient has a cancer selected from sarcoma, osteosarcoma, ovarian cancer, breast cancer, melanoma, vaginal cancer, colorectal cancer, gastric cancer, adenocarcinoma, mesothelioma, renal cancer, endometrial cancer, cholangiocarcinoma and lung cancer. 17. A method according to claim 16, in which the patient has a cancer selected from sarcoma, breast cancer, gastric cancer, vaginal cancer, cholangiocarcinoma and adenocarcinoma. 18. A medical kit for administering ET-743 in combination with capecitabine, comprising a supply of ET-743 in dosage units for at least one cycle, wherein each dosage unit contains the appropriate amount of ET-743 for the treatments and a pharmaceutically acceptable carrier, and printed instructions for administering ET-743 according to a dosing schedule. 19. The method according to claim 4, wherein capecitabine is administered in a dosage of about 2000 mg/m2/day. 20. The method according to claim 4, wherein capecitabine is administered in a dosage of about 1600 mg/m2/day. 21. The method according to claim 5, wherein ET-743 is administered in a dose range between 0.9 and 1.2 mg/m2. 22. The method according to claim 5, wherein ET-743 is administered in a dosage of about 0.9 mg/m2. 23. The method according to claim 5, wherein ET-743 is administered in a dosage of about 0.9 mg/m2 on day 1 of a 3 week cycle. 24. The method according to claim 2, wherein capecitabine is administered in a dosage of about 1600 mg/m2/day and ET-743 is administered in a dosage range between 0.9 and 1.2 mg/m2. 25. The method according to claim 24, wherein the infusion of ET-743 is carried out on day 1 and the administration of capecitabine from days 2 to 15, every 21 days. 26. The method according to claim 9, wherein commencement of administration of capecitabine is on a day after ET-743 administration.